Diss. (sammanfattning) Stockholm : Karol. inst., 2002. / Härtill 4 uppsatser.

Submitted by Haroudo Xavier Filho (haroudo.xavierfo@ufpe.br) on 2016-04-22T16:09:31Z No. of bitstreams: 2 license_rdf: 1232 bytes, checksum: 66e71c371cc565284e70f40736c94386 (MD5) Final Dissertção.pdf: 2617689 bytes, checksum: c147bcfc357fc3a4030f61766ed9bad5 (MD5) / Made available in DSpace on 2016-04-22T16:09:31Z (GMT). No. of bitstreams: 2 license_rdf: 1232 bytes, checksum: 66e71c371cc565284e70f40736c94386 (MD5) Final Dissertção.pdf: 2617689 bytes, checksum: c147bcfc357fc3a4030f61766ed9bad5 (MD5) Previous issue date: 2015-03-06 / CNPq / A abordagem mais promissora para um diagnóstico eficaz da Leishmaniose Visceral (LV) utiliza ensaios sorológicos com proteínas recombinantes, pois apresentam grande sensibilidade e especificidade, associados a baixo custo e fácil execução. Misturas de alguns antígenos geram resultados mais promissores, contudo, a produção destas aumenta os custos e dificulta a padronização. É ideal a produção de uma única proteína quimérica que apresente boa sensibilidade e seja eficiente no diagnóstico das formas humana e canina da LV. Este estudo objetivou avaliar as condições para expressão em Escherichia coli de genes sintéticos codificando proteínas quiméricas compostas por regiões selecionadas de antígenos previamente identificados de Leishmania infantum. Quatro genes, contendo os mesmos antígenos em diferentes combinações, foram otimizados para expressão em procariotos e sintetizados. Sítios internos de restrição foram incluídos nas sequências de forma a permitir a eliminação seletiva de segmentos específicos e se avaliar o efeito na expressão bacteriana da presença de diferentes regiões antigênicas, bem como de um peptídeo estimulador da tradução. A expressão das proteínas geradas foi então avaliada através de ensaios de Western Blot. Os resultados obtidos mostraram uma expressão equivalente, porém limitada, das diferentes proteínas quiméricas, independente da sua composição antigênica. Proteínas menores tiveram resultados mais promissores na expressão e o peptídeo estimulador da tradução foi essencial para otimizar essa expressão, porem ainda faz-se necessário mais estudos avaliando a sensibilidade e especificidade dessas proteínas para o diagnóstico da LV. / The most promising approach for effective diagnosis of Visceral Leishmaniasis (VL) uses serological assays with recombinant proteins, since they have high sensitivity and specificity associated with low cost and easy implementation. Mixtures of some antigens generate the most promising results, however, these increase production costs and impairs its standardization. The best option would be the production of a single chimeric protein showing good sensitivity and being effective for the diagnosis of the human and canine forms of VL. This study aimed to evaluate the conditions for expression in Escherichia coli of synthetic genes encoding chimeric proteins composed of selected regions of previously identified antigens of Leishmania infantum. Four genes, containing the same antigens in different combinations, were optimized for expression in prokaryotes and synthesized. Internal restriction sites were included in the sequences to allow selective removal of specific segments and to evaluate the effect on the bacterial expression of the presence of different antigenic regions, as well as a translational enhancer peptide. The expression of proteins generated was then evaluated by Western blot assays. The results showed equivalent expression, however limited, of the different chimeric proteins, regardless of their antigenic composition. Smaller proteins produced more promising results in the expression and the translation enhancer peptide was important to optimize this expression, however further studies are still necessary to evaluate the sensitivity and specificity of these proteins for the diagnosis of VL.

Modified Viral Protein 7 (VP7) of African horsesickness virus (AHSV) is being investigated as a peptide display protein. The protein represents a good candidate for recombinant peptide display due to its tertiary structure, which contains flexible hydrophilic loops on the top domain of the protein where small peptides can potentially be inserted. In addition, wild type (WT) AHSV VP7 tends to form hexagonal crystals of predictable shape and size when expressed in a recombinant expression system. Previous research has resulted in a number of AHSV VP7 genes containing modified cloning sites where DNA representing immunologically relevant peptides can be inserted. When these chimeric proteins are expressed the peptides should be displayed on the surface of the VP7 platform. Several studies have tested the ability to insert peptides of varying lengths into these sites and successfully express the chimeric protein. In these past cases, successful expression of a recombinant chimeric protein was gauged by the observation of particles formed by multimers of VP7 proteins that resemble the one formed by WT-VP7. However, little is known about the ability of these chimeric proteins to act as successful peptide presentations vectors. Specifically, it is not known whether the fusion peptides would retain their correct tertiary structure, or indeed be displayed to the surrounding environment in order to generate a specific immune response. Furthermore, there has been no investigation to track these chimeric proteins’ expression in a heterologous expression system. This dissertation attempts to answer several of these questions through the use of a fluorescent protein, enhanced green fluorescent protein (eGFP), as a model peptide. The use of eGFP as a model peptide can prove correct tertiary structure of the fusion peptide via function of the protein (fluorescence), as well as act as a means of monitoring expression of chimeric VP7-eGFP proteins. Chapter 1 of this dissertation reviews literature that is relevant to AHSV VP7 and the use of fluorescent proteins as fluorescent markers. In addition, the recombinant expression of proteins is discussed, with a focus on solubility and expression levels of expressed proteins. Next, a brief overview is given with regards to vaccination strategies that can be undertaken, with a focus on subunit vaccines and their viability as successful alternatives to live-attenuated vaccines. Finally, the progress with regards to using modified AHSV VP7 as a peptide presentation vector is discussed. Chapter 2 investigates the chimeric protein VP7-177-eGFP, including its construction via a recombinant DNA cloning strategy, its expression in Insect cells using a recombinant Baculovirus expression system, and the ability of eGFP to act as a model fusion peptide on the top domain of a modified VP7 protein. Several experiments investigate whether the chimeric protein maintains its tertiary structure under a series of purification steps, and investigate the solubility of the chimeric protein throughout the expression cycle. Finally, purified forms of the chimeric protein are examined for their ability to generate an immune response specific to the fusion protein, eGFP.<p / Dissertation (MSc)--University of Pretoria, 2011. / Genetics / unrestricted

Developing targeted genome regulation approaches holds much promise for accelerating trait discovery and development in agricultural biotechnology. Clustered Regularly Interspaced Palindromic Repeats (CRISPRs)/CRISPR associated (Cas) system provides bacteria and archaea with an adaptive molecular immunity mechanism against invading nucleic acids through phages and conjugative plasmids. The type II CRISPR/Cas system has been adapted for genome editing purposes across a variety of cell types and organisms. Recently, the catalytically inactive Cas9 (dCas9) protein combined with guide RNAs (gRNAs) were used as a DNA-targeting platform to modulate the expression patterns in bacterial, yeast and human cells. Here, we employed this DNA-targeting system for targeted transcriptional regulation in planta by developing chimeric dCas9-based activators and repressors. For example, we fused to the C-terminus of dCas9 with the activation domains of EDLL and TAL effectors, respectively, to generate transcriptional activators, and the SRDX repression domain to generate transcriptional repressor. Our data demonstrate that the dCas9:EDLL and dCas9:TAD activators, guided by gRNAs complementary to promoter elements, induce strong transcriptional activation on episomal targets in plant cells. Moreover, our data suggest that the dCas9:SRDX repressor and the dCas9:EDLL and dCas9:TAD activators are capable of markedly repressing or activating, respectively, the transcription of an endogenous genomic target. Our data indicate that the CRISPR/dCas9:TFs DNA targeting system can be used in plants as a functional genomic tool and for biotechnological applications.

Šio darbo tikslas buvo gauti monokloninius antikūnus prieš Hendra ir Nipah virusų nukleokapsidės baltymus. Dėl didelės Henipavirus genties virusų nukleokapsidės baltym�� homologijos sunku gauti monokloninius antikūnus, specifiškus konkretaus viruso nukleokapsidės baltymui. Siekiant išspręsti šią problemą, buvo panaudoti chimeriniai rekombinantiniai baltymai, sukonstruoti pelės poliomos viruso pagrindinio kapsidės baltymo VP1 pagrindu, į kurį buvo įterptos nehomologiškos Nipah ir Hendra virusų nukleokapsidės baltymų sekos. Imunizacijoms panaudojus tokius chimerinius baltymus, buvo nustatyta, kad jie sukelia stiprų imuninį atsaką. Buvo sukurti nauji monokloniniai antikūnai, specifiški tik Nipah viruso nukleokapsidės baltymui ir nereaguojantys su Hendra viruso nukleokapsidės baltymu. Taip pat buvo sukurti monokloniniai antikūnai prieš baltymą-nešiklį – pelės poliomos viruso pagrindinį kapsidės baltymą VP1. Naujai sukurtų antikūnų specifiškumas buvo patvirtintas imunofermentinės analizės ir imunoblotingo metodais. Monokloninių antikūnų prieš Hendra viruso nukleokapsidės baltymą gauti nepavyko. / The aim of this study was to generate monoclonal antibodies against Hendra and Nipah virus nucleocapsid proteins. There is high homology between nucleocapsid proteins of Henipavirus genus members, therefore it is difficult to generate monoclonal antibodies that do not show any cross-reactivity with both antigens. This problem was solved by using recombinant chimeric proteins designed by insertion of non-homological segments of Hendra and Nipah virus nucleocapsid proteins into the mouse polyomavirus capsid protein VP1. Mice were immunized with these chimeric proteins and it was determined that they induce a strong immune response. Monoclonal antibodies against Nipah virus nucleocapsid protein as well as carrier protein – mouse polyomavirus capsid protein VP1 – were generated. The specificities of newly developed monoclonal antibodies were confirmed by ELISA and immunoblot. The generation of specific monoclonal antibodies against Hendra virus nucleocapsid protein failed.

Suite au projet de séquençage du génome d’Arabidopsis thaliana, plus de 400 récepteurs de types serine/thréonine kinases (Protein Receptor Kinase ou PRK) ont été prédits. Par contre, seulement sept paires de récepteurs/ligands ont été caractérisées jusqu’à présent par des techniques de biochimie et d’analyse, de mutants. Parmi ceux-ci figurent les PRK : BRI1, CLV1, SRK, SR160, Haesa-IDA et PEPR1 qui jouent un rôle important dans le développement, l’auto-incompatibilité sporophytique et les mécanismes de défense. Le but de mon projet de maîtrise était de développer un bioessai à haut débit qui permettra la découverte de ligands peptidiques. Le bioessai utilisera des PRK chimériques composés du domaine extracellulaire (l’ectodomaine) de la PRK à l’étude fusionnée au domaine intracellulaire d’une PRK qui agira comme rapporteur. Deux stratégies sont présentement développées dans notre laboratoire : la première consiste à fusionner la PRK à l’étude avec le domaine intracellulaire (l’endodomaine) du récepteur tyrosine kinase animal EGFR (Epidermal Growth Factor Receptor). Suite à l’interaction avec une fraction protéique contenant un ligand correspondant à la PRK étudiée, une transphosphorylation de l’endodomaine (le domaine kinase) serait détectable. La seconde stratégie utilise l’endodomaine du récepteur BRI1, un récepteur répondant aux brassinostéroïdes. Suite à l’interaction avec une fraction protéique contenant un ligand correspondant à la PRK étudiée, cette fois-ci nous devrions être en mesure de mesurer l’activation d’un gène rapporteur répondant normalement à une activation par les brassinostéroïdes. / The complete sequence of the genome of Arabidopsis thaliana was achieved in year 2000 and has resulted in the prediction of more than 400 receptor serine/threonine kinase or Plant Receptor Kinase (PRK). Despite this tremendous work, only seven pairs of ligand/receptor have been characterized through conventional techniques such as mutant analysis and biochemical characterization. These receptors have been found to play an important role in plant defense (SP160), development (BRI1, CLV1) and sporophytic autoincompatibility (SRK). The aim of the project was to develop a high throughput bioassay in order to find new ligands for known receptors. In order to do so, the bioassay will use chimeric protein technology, by fusing the ectodomain of a receptor to a known endodomaine. The latter will play the role of a reporter. Two strategies were developed in our laboratory and are being tested. The first strategy is to fuse the ectodomain of an unknown PRK to the phylogeneticaly unrelated kinase domain of the animal Epidermal Grown Factor Receptor (EGFR). When tested with a crude protein extract containing the specific ligand of the unknown PRK, a transphosphorylation should occur and be detected. The second strategy will use the endodomain of BRI1 as a reporter, a receptor responding to the brassinosteroid phytohormone, which will relay the message to a second construct used as a reporter gene once the ligand has bound the PRK ectodomain fused to the BRI1 endodomain.

Suite au projet de séquençage du génome d’Arabidopsis thaliana, plus de 400 récepteurs de types serine/thréonine kinases (Protein Receptor Kinase ou PRK) ont été prédits. Par contre, seulement sept paires de récepteurs/ligands ont été caractérisées jusqu’à présent par des techniques de biochimie et d’analyse, de mutants. Parmi ceux-ci figurent les PRK : BRI1, CLV1, SRK, SR160, Haesa-IDA et PEPR1 qui jouent un rôle important dans le développement, l’auto-incompatibilité sporophytique et les mécanismes de défense. Le but de mon projet de maîtrise était de développer un bioessai à haut débit qui permettra la découverte de ligands peptidiques. Le bioessai utilisera des PRK chimériques composés du domaine extracellulaire (l’ectodomaine) de la PRK à l’étude fusionnée au domaine intracellulaire d’une PRK qui agira comme rapporteur. Deux stratégies sont présentement développées dans notre laboratoire : la première consiste à fusionner la PRK à l’étude avec le domaine intracellulaire (l’endodomaine) du récepteur tyrosine kinase animal EGFR (Epidermal Growth Factor Receptor). Suite à l’interaction avec une fraction protéique contenant un ligand correspondant à la PRK étudiée, une transphosphorylation de l’endodomaine (le domaine kinase) serait détectable. La seconde stratégie utilise l’endodomaine du récepteur BRI1, un récepteur répondant aux brassinostéroïdes. Suite à l’interaction avec une fraction protéique contenant un ligand correspondant à la PRK étudiée, cette fois-ci nous devrions être en mesure de mesurer l’activation d’un gène rapporteur répondant normalement à une activation par les brassinostéroïdes. / The complete sequence of the genome of Arabidopsis thaliana was achieved in year 2000 and has resulted in the prediction of more than 400 receptor serine/threonine kinase or Plant Receptor Kinase (PRK). Despite this tremendous work, only seven pairs of ligand/receptor have been characterized through conventional techniques such as mutant analysis and biochemical characterization. These receptors have been found to play an important role in plant defense (SP160), development (BRI1, CLV1) and sporophytic autoincompatibility (SRK). The aim of the project was to develop a high throughput bioassay in order to find new ligands for known receptors. In order to do so, the bioassay will use chimeric protein technology, by fusing the ectodomain of a receptor to a known endodomaine. The latter will play the role of a reporter. Two strategies were developed in our laboratory and are being tested. The first strategy is to fuse the ectodomain of an unknown PRK to the phylogeneticaly unrelated kinase domain of the animal Epidermal Grown Factor Receptor (EGFR). When tested with a crude protein extract containing the specific ligand of the unknown PRK, a transphosphorylation should occur and be detected. The second strategy will use the endodomain of BRI1 as a reporter, a receptor responding to the brassinosteroid phytohormone, which will relay the message to a second construct used as a reporter gene once the ligand has bound the PRK ectodomain fused to the BRI1 endodomain.